Grigory Dukor / Reuters Russia's Central Bank Governor Sergei Ignatyev has generally kept a low profile during his 11-year tenure. By Douglas Busvine and Katya Golubkova, Reuters MOSCOW - Nearly $50 billion was transferred out of Russia illegally in 2012 and more than half this sum may have been controlled by a single group of people, the country's central bank said on Wednesday. Sergei Ignatyev, chairman of the Bank of Russia, was citing the findings of a study that the bank said it would publish later on Wednesday. "You get the impression that they (half the transfers) are all controlled by one well-organized group of people," Sergei Ignatyev, chairman of the Bank of Russia, told the Vedomosti daily in an interview. Ignatyev, who is due to retire in June, declined to identify the group in response to a reporter's question at the Federation Council, the upper house of parliament, where he was due to deliver an address. But the central bank analysis appears to be an indictment of President Vladimir Putin's brand of state capitalism, which critics say has allowed official corruption to flourish on a huge scale. 'Bribes and kickbacks'It also marks an unusually strong intervention by Ignatyev, who … Continue reading →

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/nrl69c/global) has announced the addition of the "Global Endocrinology Drugs Market 2012-2016" report to their offering. TechNavio's analysts forecast the Global Endocrinology Drugs market to grow at a CAGR of 7.58 percent over the period 2012-2016. One of the key factors contributing to this market growth is the introduction of new drugs. The Global Endocrinology Drugs market has also been witnessing the increase in market consolidation. However, the off-label use of the human growth hormone could pose a challenge to the growth of this market. The key vendors dominating this market space are Abbott Laboratories, Eli Lilly and Co., Novartis AG, and Pfizer Inc. The other vendors mentioned in the report are Acrux Ltd, Alacer Corp., Alcon Inc., ChemGen Corporation., Excaliard Pharmaceuticals Inc, F. Hoffmann La Roche, Facet Biotech Corporation, Ferrosan Holding A/S, FoldRx Pharmaceuticals Inc., Genoptix Inc., Janssen Pharmaceutica NV, King Pharmaceuticals Inc., Laboratorio Teuto Brasileiro S.A., NextWave Pharmaceuticals Inc., Novo Nordisk A/S, Pharmacia Corporation, Piramal Healthcare Limited, Solvay Pharmaceuticals Inc., STARLIMS Technologies Ltd., and Zhejiang Tianyuan Bio-Pharmaceutical Co. Ltd. Commenting on the report, an analyst from TechNavio's Healthcare team said: ''The Global Endocrinology Drugs market is witnessing the introduction of innovative and improved … Continue reading →

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/4j7npr/orphan_drugs) has announced the addition of the "Orphan Drugs Partnering Terms and Agreements" report to their offering. The Orphan Drugs Partnering Agreements report provides an understanding and access to the orphan drugs partnering deals and agreements entered into by the worlds leading healthcare companies. - Trends in orphan drugs partnering deals - Disclosed headlines, upfronts, milestones and royalties by stage of development - Orphan drugs partnering contract documents - Top orphan drugs deals by value The OrphanDrugs Partnering Terms and Agreements report provides an understanding and access to the orphan drugs partnering deals and agreements entered into by the worlds leading healthcare companies. The report provides an understanding and analysis of how and why companies enter orphan drugs partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors orphan drugs technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies … Continue reading →